Surgical morbidity in retroperitoneal sarcoma resection

Surgical morbidity in retroperitoneal sarcoma resection INTRODUCTIONSurgery is the mainstay of curative‐intent treatment for retroperitoneal sarcoma (RPS). Given that these tumors typically grow to a considerable size prior to detection and can often involve multiple organs, definitive surgery frequently requires a complex, multivisceral resection. In order to devise tailored treatment strategies for individual patients and to counsel them accordingly, sarcoma surgeons must be able to appreciate the anticipated morbidity of a proposed procedure. The literature surrounding the short‐ and long‐term outcomes following resection of RPS is scant and limited by considerable heterogeneity in patient populations and surgical approach. Accepting these limitations, the data available to guide decision‐making are reviewed here.EXTENT OF SURGERY AND SHORT‐TERM MORBIDITYOver the past decade, there has been a paradigm shift toward a radical surgical approach to RPS. In 2009, two European centers published data suggesting improved oncologic outcomes with liberal en bloc resection of organs adhering to, but not necessarily invaded by, RPS. Gronchi et al reported significantly reduced local recurrence rates with radical resection compared to an historical cohort who underwent marginal excision at the same institution. With longer follow‐up, this improvement in local control was found to be associated with improved overall survival. The evolution toward more radical resection http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Surgical Oncology Wiley

Surgical morbidity in retroperitoneal sarcoma resection

Loading next page...
 
/lp/wiley/surgical-morbidity-in-retroperitoneal-sarcoma-resection-bk4yk5dqKu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0022-4790
eISSN
1096-9098
D.O.I.
10.1002/jso.24902
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONSurgery is the mainstay of curative‐intent treatment for retroperitoneal sarcoma (RPS). Given that these tumors typically grow to a considerable size prior to detection and can often involve multiple organs, definitive surgery frequently requires a complex, multivisceral resection. In order to devise tailored treatment strategies for individual patients and to counsel them accordingly, sarcoma surgeons must be able to appreciate the anticipated morbidity of a proposed procedure. The literature surrounding the short‐ and long‐term outcomes following resection of RPS is scant and limited by considerable heterogeneity in patient populations and surgical approach. Accepting these limitations, the data available to guide decision‐making are reviewed here.EXTENT OF SURGERY AND SHORT‐TERM MORBIDITYOver the past decade, there has been a paradigm shift toward a radical surgical approach to RPS. In 2009, two European centers published data suggesting improved oncologic outcomes with liberal en bloc resection of organs adhering to, but not necessarily invaded by, RPS. Gronchi et al reported significantly reduced local recurrence rates with radical resection compared to an historical cohort who underwent marginal excision at the same institution. With longer follow‐up, this improvement in local control was found to be associated with improved overall survival. The evolution toward more radical resection

Journal

Journal of Surgical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off